Addressing Facial Volume Loss

juvederm_voluma

There’s good news for those seeking to restore a rounder, fuller midface section and a subsequent softer, more youthful appearance. Face contouring and volume restoring Juvéderm Voluma XC is expected to receive final FDA approval by the end of 2013.

In May the FDA’s General and Plastic Surgery Devices Panel Advisory Committee voted unanimously that the benefits of this injectable hyaluronic acid dermal filler outweigh the risks. Juvéderm Voluma XC is intended for cheek augmentation to correct age and weight-loss related volume deficit in the mid-face region.

Multiple dermal fillers have already been approved for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). Recently there’s been a shift to address overall volume loss versus simply filling wrinkles and folds. Hence the development of Juvéderm Voluma XC which is brought to you by Allergan, Inc., the same people behind Botox and Juvéderm.

“Today’s recommendation is an important step in the FDA review process for Juvéderm Voluma XC,” said Scott M. Whitcup MD, executive vice president of research and development and chief scientific officer of Allergan, on the day the news first broke. “Allergan is committed to working with the FDA as they continue their review of our pre-market approval process for Juvéderm Voluma XC, with the goal of providing consumers with the first treatment option that has been specifically developed to help restore cheek volume that has been lost over time.”

Once approved, Juvéderm Voluma XC would the first and only dermal filler in the U.S. specifically designated for cheek augmentation. If you’ve experienced a noticeable thinning in your cheeks and cheekbone area over time, whether through weight loss or the natural aging process, Juvéderm Voluma XC might be worth your consideration early next year.

CLOSE
CLOSE